Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

NCT07484022 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Urothelial Cancer
Metastatic Urothelial Carcinoma

Interventions

DRUG: GB-4362
DRUG: enfortumab vedotin (EV)
DRUG: Pembrolizumab

Sponsor

Generate Biomedicines